No clear answer to patient no-show struggle

Laura Pedulli | | Health Exec | Precision Medicine

 

Do patients have a responsibility when they fail to follow-up with their physicians? Barron H. Lerner, MD, and professor of medicine and population health at NYU School of Medicine, explores this hazy ethical area in a New York Times editorial.

“If one argues that doctors or their colleagues need to call all people who miss appointments, why shouldn’t we also be calling every day to make sure patients are taking their medications, exercising or adhering to their diets?,” he wrote.

Read more below:

When Patients Don’t Follow Up

Laura Pedulli

Related Content

Pitching the business case for 3D printing labs in radiology
FDA issues first-ever clearance for OTC oximeter
Augmented reality company secures $15M in funding from Cleveland Clinic, Mayo, GE Healthcare and more
Merck to acquire Prometheus Biosciences for $10.8B
Johnson & Johnson scraps RSV vaccine after trial
Intermountain Health launches new biotech company

Around the web

Cardiovascular Business
FDA says years-long tirzepatide shortage is resolved, will give limited leeway to compounders

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

AI in Healthcare
From Capitol Hill to a hospital near you? 5 federal recommendations for healthcare AI policy

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Cardiovascular Business
Merck spends up to $2B to license new weight loss drug with potential heart benefits

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.